Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | STAT6 | P42226 | 5/20 | 0.43 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 6/20 | 0.42 |
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | JAK1 | P23458 | 4/20 | 0.42 |
| ▸ | TYK2 | P29597 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524302 | 0.90 | IGF1R (0.44) | EGFRBTKSTAT6FLT3JAK2 | |
| SCHEMBL15524415 | 0.87 | CNR2 (0.48) | BTKSTAT6CNR2 | |
| SCHEMBL15524515 | 0.85 | FLT4 (0.41) | EGFRBTKITK | |
| SCHEMBL15524487 | 0.82 | STAT6 (0.44) | EGFRSTAT6ITKJAK3 | |
| SCHEMBL15524121 | 0.81 | SYK (0.51) | STAT6 | |
| SCHEMBL15524392 | 0.80 | STAT6 (0.50) | BTKSTAT6JAK2AXL | |
| SCHEMBL15524377 | 0.80 | CAMK2D (0.43) | EGFRBTKSTAT6ITKFLT3 | |
| SCHEMBL15524585 | 0.79 | PTK2 (0.45) | BTKCNR2 | |
| SCHEMBL15524738 | 0.79 | FLT4 (0.40) | EGFRBTKSTAT6ITKJAK2 | |
| SCHEMBL15524080 | 0.77 | CCND3 (0.58) | STAT6JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | EGFR 30/4885BTK 351/4885STAT6 4087/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | EGFR 14/4885BTK 399/4885STAT6 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.